Nasopharyngeal carcinoma laboratory findings
|
Nasopharyngeal carcinoma Microchapters |
|
Differentiating Nasopharyngeal carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Nasopharyngeal carcinoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Nasopharyngeal carcinoma laboratory findings |
|
Risk calculators and risk factors for Nasopharyngeal carcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]
Overview
Laboratory findings consistent with the diagnosis of nasopharyngeal carcinoma include an elevated concentration of serum EBV titer. Plasma EBV DNA load, EBV viral capsid antigen, assessment of EBV in the pathologic specimens, Complete blood count, Urea and creatinine, electrolytes, Liver function tests, Calcium and phosphate, and Alkaline phosphatase are the tests which should be done for the diagnosis and assessment of tumor invasion, and differentiation of tumor.
Laboratory Findings
- An positive concentration of serum EBV DNA is diagnostic of nasopharyngeal carcinoma.[1][2][3][4]
- The laboratory tests which should be done for the diagnosis and assessment of tumor invasion, and differentiation of tumor are:[5][6][7]
- Plasma EBV DNA load by PCR
- EBV viral capsid antigen
- Detection of EBV in the pathologic specimens by immunohistochically staining for latent membtane protein (LMP) or in situ hybridization for EBV-encoded RNA (EBER)
- Complete blood count (CBC)
- Urea and creatinine
- Electrolytes
- Liver function tests
- Calcium and phosphate
- Alkaline phosphatase
References
- ↑ Wei, William I; Sham, Jonathan ST (2005). "Nasopharyngeal carcinoma". The Lancet. 365 (9476): 2041–2054. doi:10.1016/S0140-6736(05)66698-6. ISSN 0140-6736.
- ↑ Wei, Qing-Yi; Jin, Hekun; Xie, Xiaoxue; Wang, Hui; Hu, Jun; Liu, Feng; Liu, Zhigang; Zhou, Jumei; Zhang, Yingying; Xi, Xuping; Hu, Bingqiang; Liao, Yuping; Tang, Jingtian (2014). "ERCC1 Cys8092Ala and XRCC1 Arg399Gln Polymorphisms Predict Progression-Free Survival after Curative Radiotherapy for Nasopharyngeal Carcinoma". PLoS ONE. 9 (7): e101256. doi:10.1371/journal.pone.0101256. ISSN 1932-6203.
- ↑ Lin, De-Chen; Meng, Xuan; Hazawa, Masaharu; Nagata, Yasunobu; Varela, Ana Maria; Xu, Liang; Sato, Yusuke; Liu, Li-Zhen; Ding, Ling-Wen; Sharma, Arjun; Goh, Boon Cher; Lee, Soo Chin; Petersson, Bengt Fredrik; Yu, Feng Gang; Macary, Paul; Oo, Min Zin; Ha, Chan Soh; Yang, Henry; Ogawa, Seishi; Loh, Kwok Seng; Koeffler, H Phillip (2014). "The genomic landscape of nasopharyngeal carcinoma". Nature Genetics. 46 (8): 866–871. doi:10.1038/ng.3006. ISSN 1061-4036.
- ↑ Peng Zhang, Song-Ke Wu, Ying Wang, Zi-Xuan Fan, Chu-Rong Li, Mei Feng, Peng Xu, Wei-Dong Wang & Jin-Yi Lang (2015). "p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study". Oncology letters. 9 (1): 113–118. doi:10.3892/ol.2014.2631. PMID 25435943. Unknown parameter
|month=ignored (help) - ↑ Pastor, M.; Lopez Pousa, A.; del Barco, E.; Perez Segura, P.; Astorga, B. Gonzalez; Castelo, B.; Bonfill, T.; Martinez Trufero, J.; Grau, J. Jose; Mesia, R. (2017). "SEOM clinical guideline in nasopharynx cancer (2017)". Clinical and Translational Oncology. 20 (1): 84–88. doi:10.1007/s12094-017-1777-0. ISSN 1699-048X.
- ↑ Brennan, Bernadette (2006). "Nasopharyngeal carcinoma". Orphanet Journal of Rare Diseases. 1 (1). doi:10.1186/1750-1172-1-23. ISSN 1750-1172.
- ↑ Muhyi Al-Sarraf & Maryada S. Reddy (2002). "Nasopharyngeal carcinoma". Current treatment options in oncology. 3 (1): 21–32. PMID 12057084. Unknown parameter
|month=ignored (help)